Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives
Iman Abou Dalle, Rémy Duléry, Nour Moukalled, Laure Ricard, Nicolas Stocker, Jean El Cheikh, Mohamad Mohty, Ali Bazarbachi
Abstract
Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.